Skip to main content
2025 ASCRS Annual Scientific Meeting Main banner
Final Program


Visit ASCRS U
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Self-Assessment
Self-Assessment
Social
Social
Industry
Industry
Back

Session: ePoster: Colon and Colorectal Cancer 20 (Tue8)

EP941 - Comparative Survival Analysis of Trifluridine/Tipiracil + Bevacizumab Versus Regorafenib in Metastatic Colorectal Cancer: Insights from a Real-World TriNetX Database Study

Tuesday, May 13, 2025
8:10 AM – 8:15 AM PT

    ePoster Presenter(s)

  • CHIH AN LIN, MD, Colorectal Surgeon

    Attending physician
    Taichung Veterans General Hospital, Department of Colorectal Surgery
    TAICHUNG, Taichung, Taiwan (Republic of China)

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

    • Senior Author(s)

  • Chang Lin Lin

    Attending physician
    colorectal surgery
    Taichung, Taichung, Taiwan (Republic of China)

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

All of the relevant financial relationships listed below have been mitigated.
CHIH AN LIN, MD, Colorectal Surgeon: This individual has no financial relationships with ineligible companies.
Chang Lin Lin: This individual has no financial relationships with ineligible companies.
Image or Table (Do Not add text here):

Purpose/Background: Colorectal cancer is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related deaths. For metastatic colorectal cancer (mCRC), the five-year survival rate is approximately 15%. Trifluridine/tipiracil (FTD/TPI, also known as TAS-102) and regorafenib are the standard third-line treatments for chemotherapy-refractory mCRC. The SUNLIGHT study demonstrated that adding bevacizumab to FTD/TPI significantly improved overall survival (OS). This study evaluates real-world survival outcomes of FTD/TPI + bevacizumab compared to FTD/TPI alone and regorafenib using the TriNetX global research network.

Methods/Interventions: This retrospective cohort study utilized the TriNetX global research network, which includes data from 127 healthcare organizations across multiple countries and over 300 million patients. Patients with mCRC were identified using ICD-10 codes for colon, rectosigmoid junction, and rectal cancers from 2015 to 2023. The study population was categorized into three cohorts: FTD/TPI alone, FTD/TPI + bevacizumab, and regorafenib. Propensity score matching was used to balance baseline characteristics such as age, sex, ECOG performance status, and comorbidities. The primary outcome was OS, measured from the start of third-line therapy until death or last follow-up. Secondary outcomes included PFS and treatment-related adverse events. Survival analyses were performed using Kaplan-Meier curves and Cox proportional hazards models, with HR and 95% CI reported for comparisons.

Results/Outcomes: A total of 5,213 patients met the initial inclusion criteria: 501 in the FTD/TPI + bevacizumab group, 3,937 in the FTD/TPI group, and 2,775 in the regorafenib group. After propensity score matching, two direct comparisons were conducted to assess the survival impact of FTD/TPI + bevacizumab. In the first comparison, FTD/TPI + bevacizumab was evaluated against FTD/TPI alone, resulting in a matched cohort of 499 patients in each group. The median OS was significantly longer in the FTD/TPI + bevacizumab group compared to the FTD/TPI monotherapy group (12.7 months vs. 9.0 months, HR = 0.782, 95% CI = 0.667–0.916, p < 0.002). The Kaplan-Meier survival curves indicated a clear separation, favoring the FTD/TPI + bevacizumab combination in terms of OS.

The second comparison analyzed FTD/TPI + bevacizumab against regorafenib, resulting in a matched cohort of 499 patients in each group. Similarly, the median OS was significantly longer in the FTD/TPI + bevacizumab group compared to the regorafenib group (12.5 months vs. 9.4 months, HR = 0.814, 95% CI = 0.694–0.954, p = 0.011). The Kaplan-Meier survival curves demonstrated a significant survival advantage in favor of the FTD/TPI + bevacizumab group, suggesting a more favorable outcome compared to single-agent regorafenib.

Conclusion/Discussion: This real-world analysis using the TriNetX network supports the SUNLIGHT study findings, showing that FTD/TPI with bevacizumab provides superior survival benefits over FTD/TPI alone and regorafenib in chemotherapy-refractory mCRC patients. These results confirm FTD/TPI + bevacizumab as a strong third-line option. This study emphasizes the need to consider FTD/TPI + bevacizumab as a preferred strategy for mCRC patients who have exhausted standard chemotherapy. Further prospective studies are needed to validate these findings and refine treatment strategies.